Our lastest news on Orsiro and Orsiro Mission DES

06
May
2020
| 09:24 Europe/Amsterdam
According to recently presented TICO trial data, patients with acute coronary syndrome (ACS) treated with BIOTRONIK’s Orsiro drug eluting stent (DES) benefit from stopping aspirin three months after
24
February
2020
| 00:00 Europe/Amsterdam

BIOTRONIK’s Ultrathin Strut Orsiro Coronary Drug-Eluting Stent Continues to Deliver Excellent Results After Three Years

Data from BIOFLOW-V Trial Presented at CRT and Published in JACC: Cardiovascular Interventions Reinforces Orsiro’s Ability to Outperform Abbott’s Xience

BIOTRONIK today announced three-year data from the BIOFLOW-V trial, which was presented yesterday at the 2020 CRT Congress. The three-year follow-up data demonstrates consistently lower clinical
21
February
2020
| 14:11 Europe/Amsterdam

BIOTRONIK Introduces Next Generation Drug-Eluting Stent System in the CE Region

Orsiro Mission Provides the Next Level of Deliverability for the Orsiro Stent

BIOTRONIK has announced CE Mark certification for the Orsiro Mission drug-eluting stent (DES) system. The next generation of the company’s ultrathin strut Orsiro DES provides higher deliverability
30
October
2019
| 00:00 Europe/Amsterdam

Orsiro Coronary Drug-Eluting Stent Receives Market Approval in China

BIOTRONIK’s Ultrathin-Strut Drug-Eluting Stent Soon Available in China Following Market Approval

BIOTRONIK announced today that its Orsiro coronary drug-eluting stent (DES) has been approved for sale in China by the National Medical Products Administration. The company expects to make the device
18
October
2019
| 14:54 Europe/Amsterdam
About 30 percent of patients undergoing primary percutaneous coronary intervention (PCI) suffer from ST-Elevation Myocardial Infarction (STEMI) – the most acute form of coronary artery disease. It’s caused by a complete thrombotic occlusion and is
21
May
2019
| 00:00 Europe/Amsterdam

Late-Breaking Data at EuroPCR: Orsiro Demonstrates Unique Benefits in Small Vessels

A Subgroup Analysis of the BIO-RESORT RCT Three-Year Data Showed Significant Differences in Efficacy in Favor of Ultrathin Strut Orsiro

Focusing on patients with small vessels, three-year outcomes of the BIO-RESORT randomized controlled trial (RCT) showed a significantly lower target lesion revascularization (TLR) rate and thus